Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine Learning (ML)
Shots:
- Ono and InveniAI have signed a research collaboration agreement for the identification of novel therapeutic targets using the latter’s artificial intelligence (AI) and machine learning (ML)
- Under the collaboration, InveniAI will utilize its AI technologies, AlphaMeld & ChatAlphaMeld, to identify new therapeutic targets for various diseases specified by Ono. Moreover, through AI & ML algorithms along with Generative AI tools, the company will propose drug discovery hypotheses for optimization
- Ono will commence the confirmation studies to validate the hypotheses and will hold back the global exclusive development and commercialization rights of these identified drug candidates
Ref: Ono Pharmaceutical | Image: Ono Pharmaceutical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
